Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,728 across all filing types
Latest filing 2014-12-04 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于入选国家级非物质文化遗产名录的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the inclusion of its subsidiary's traditional Chinese medicine preparation in the national intangible cultural heritage list. It is a brief notice about a cultural heritage recognition, not related to financial results, management changes, or regulatory filings. The document length is only 434 characters, indicating it is a short announcement. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a general regulatory announcement about a non-financial matter, so the best fit is Regulatory Filings (RNS).
2014-12-04 Chinese
筹划非公开发行股票事项延期复牌公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the extension of a trading suspension due to the planning of a non-public stock issuance and related major corporate actions. It discusses the reasons for the suspension, including ongoing audits and approvals related to asset acquisitions and capital raising. The document is short (727 characters) and serves as a notice about the status of a capital raising event and stock suspension, not a detailed financial report or full disclosure document. It fits the category of Capital/Financing Update (CAP) because it provides updates on the company's fundraising activities and capital structure changes.
2014-12-03 Chinese
2014年第三次临时股东大会资料
AGM Information Classification · 95% confidence The document is titled as materials for the 2014 third extraordinary shareholders meeting of Kunming Pharmaceutical Group Co., Ltd. It includes detailed agenda items, voting procedures, and proposals related to changes in investment projects, specifically the reallocation of funds from a previously planned project to new projects involving subsidiaries and R&D. The document contains detailed feasibility studies, investment background, risk analysis, and project descriptions. It is clearly a set of materials prepared for a shareholders meeting to discuss and vote on specific corporate actions, including capital allocation and investment changes. There is no indication that this is a full annual or interim financial report, earnings release, or audit report. It is not a proxy solicitation or voting results announcement but rather the information and materials provided for the shareholders to review before the meeting. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or Extraordinary General Meeting. The document length (15,000 characters) and content depth support this classification with high confidence.
2014-12-01 Chinese
七届三十次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 30th meeting of the 7th Board of Directors of Kunming Pharmaceutical Group Co., Ltd. It details board decisions on capital increases in subsidiaries, credit guarantees, and plans for a shareholders' meeting. The content focuses on board meeting resolutions and approvals rather than full financial statements or detailed reports. The document length is short (1713 characters), and it is clearly a board meeting resolution announcement. Therefore, it fits best under the category of Board/Management Information (MANG).
2014-11-27 Chinese
七届十四次监事会决议公告
Capital/Financing Update Classification · 95% confidence The document is an announcement of a supervisory board resolution regarding changes to the company's fundraising investment projects. It includes voting results from the supervisory board meeting and mentions that the proposal will be submitted to a shareholders' meeting for approval. The document is short (797 characters) and primarily serves as an official announcement of a board decision related to capital investment projects. It does not contain detailed financial data or a full report. Therefore, it fits best under Capital/Financing Update (CAP).
2014-11-27 Chinese
对集团金泰得药业股份有限公司增加投资4,390万元可行性研究报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "Feasibility Study Report" for an investment increase of 43.9 million yuan into a subsidiary company. It contains detailed sections such as project background, necessity, funding usage, company overview, benefit analysis, and risk analysis. The content is focused on the feasibility and justification of the investment project rather than financial results or regulatory announcements. The document length is 4359 characters, which is relatively short but contains substantive project analysis and financial projections related to the investment. It is not an announcement of a report publication, nor a certification or regulatory filing. It is not a financial report like an annual or interim report, nor a call transcript or governance document. The nature of the document fits best with a Capital/Financing Update (CAP) as it details a capital investment project and funding usage. Therefore, the appropriate classification is CAP with high confidence.
2014-11-27 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.